Key takeaways
- • Novo Nordisk Wegovy partnership (Nov 2025) — direct brand co-brand, $199/mo intro pricing.
- • $99/mo starting — cheapest brand-only entry tier.
- • Both brand + compounded paths: rare flexibility under one provider.
- • NYSE: HIMS public-company stability ($1B+ market cap).
- • Women-targeted branding but prescribes to anyone eligible.
What Hers is
Hers (forhers.com) is the women's vertical of Hims & Hers Health Inc, founded 2017 as direct-to-consumer telehealth. Now NYSE-listed (HIMS) with ~$1B+ market cap. Weight loss vertical launched 2023, gained traction with November 2025 Novo Nordisk Wegovy partnership announcement.
Pricing breakdown
| Path | Monthly |
|---|---|
| Compounded semaglutide (starter) | $99-199/mo |
| Brand Wegovy via Novo partnership (starter) | $199/mo intro |
| Brand Wegovy maintenance — insurance copay | $25-100/mo typical |
| Brand Wegovy maintenance — cash without insurance | ~$1,349/mo list |
How Hers works
- Sign-up on forhers.com/weight-loss → intake questionnaire
- Async provider review (hours, not days)
- Patient chooses: compounded or brand Wegovy path
- Shipment 3-5 days; monthly recurring billing
- Ongoing async messaging for dose questions, refills
What Hers does well
Novo Nordisk partnership = direct brand access
Both brand AND compounded options under one roof
$99/mo cheapest brand-only entry
NYSE-listed financial stability
Strong async-first model
Multi-vertical platform (skin/mental health/etc.)
Where Hers falls short
Aggressive upsell into bundled add-ons reported in reviews
Compounded path inherits FDA enforcement risk
Brand pricing reliant on Novo partnership longevity
No labs included (Ro advantage)
Female-branded UX may alienate male patients
Cancellation friction reported in Trustpilot
Who Hers is best for
Best fit: Women-identifying patients comfortable with Hers branding. Patients who want option k toggle between brand and compounded paths. Self-pay patients seeking lowest brand-only entry ($99/mo).
Decent fit: Insurance-covered patients wanting Novo Nordisk co-brand legitimacy.
Poor fit: Male patients (use Hims instead). Patients wanting labs included (Ro better). Patients allergic to upsell pressure.
Hers vs. other GLP-1 providers — compare
SponsoredSee how Hers stacks up against other telehealth GLP-1 providers, ranked by our editorial score. Visit a partner to check current pricing and eligibility — we compare and link, we never sell medication.
Advertising disclosure: we may earn a commission if you sign up through these links, at no extra cost to you — it never affects our rankings. How we make money
FAQ
Is Hers legit?
Yes. Hers is the women's vertical of Hims & Hers Health Inc (NYSE: HIMS), a publicly-traded telehealth company founded 2017. Multi-vertical platform (mental health, dermatology, sexual health, weight loss). Licensed providers in all 50 states. Public-company financial stability.
Does Hers prescribe Wegovy?
Yes, since November 2025 via official Novo Nordisk partnership. Hers became one of first telehealth platforms with direct Novo Nordisk co-brand. Offers Wegovy alongside compounded semaglutide options.
Hers brand vs compounded — which to choose?
Brand Wegovy ($199/mo introductory pricing per Novo partnership) covers FDA-approved drug with full safety review. Compounded semaglutide (~$199/mo Hers price) is pharmacy-mixed under 503A — carries FDA enforcement risk. Brand recommended if insurance covers; compounded if paying cash + accept FDA risk.
How does pricing compare to Ro?
Hers starting $99/mo undercuts Ro ($145 enrollment + $99/mo). With Novo partnership, Hers Wegovy ~$199/mo intro vs Ro's insurance-or-list approach. Cheaper than Ro entry. Tradeoff: Hers strong female-targeted branding vs Ro multi-drug clinical orientation.
Is Hers women-only?
Hers brand markets to women, but prescribes to anyone eligible. Male-identifying patients typically use Hims (men's vertical of same parent company) with identical formulary + similar pricing. Brand split is marketing-only, not clinical.
What's the biggest weakness?
Brand-positioning pressure can feel salesy — Hers heavily upsells subscriptions + bundled add-ons. Cancellation friction reported in some Trustpilot reviews. With Novo partnership new, long-term pricing stability unproven (intro pricing could end).
Bottom line
Hers occupies a unique slot — Novo Nordisk brand partnership + compounded option + women-focused branding under one roof. $99/mo entry beats Ro's $145 enrollment. Best fit: women-identifying patients wanting brand+compounded flexibility. Compare with Ro Body, full ranking.
Sources
- Hers weight loss page — pricing reference.
- Hims & Hers investor page — Novo partnership context.
Editorial only — not medical advice. Pricing accurate as of 2026-06-05; verify with Hers before deciding.